MONTREAL, QC / ACCESSWIRE / December 9, 2016 / Sunshine Biopharma Inc. (OTC PINK: SBFM), a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications, is pleased to announce that it has signed a Strategic Alliance Agreement with Atlas Pharma Inc., a fully certified Montreal-based company offering Analytical Testing and other services to the pharmaceutical industry. Pursuant to the Agreement Sunshine and Atlas will work together, sharing infrastructure, personnel and marketing efforts to advance their respective business interest. In addition, Atlas will provide warehousing, regulatory compliance, logistics and quality control for Sunshine's recently announced Generic Pharmaceuticals Sales Operations.

About Atlas Pharma Inc.

Atlas Pharma Inc. is an analytical services laboratory providing testing and quality control of pharmaceuticals, cosmetics and natural products. Atlas has a Drug Establishment License (DEL) from Health Canada to conduct licensable activities in a building which has been inspected and assessed as being in compliance with the requirements of Good Manufacturing Practices (GMP). All testing activities and other activities of Atlas meet the standards of Good Manufacturing Practice (GMP). www.atlaspharmainc.ca

About Sunshine Biopharma Inc.

Sunshine Biopharma Inc. is a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. Sunshine Biopharma's recently announced Generic Pharmaceuticals portfolio includes:

• SBI-Anastrozole (brand name Arimidex® by AstraZenica) for treatment of Breast Cancer

• SBI-Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer

• SBI-Bicalutamide (brand name Casodex® by AstraZenica) for treatment of Prostate Cancer

• SBI-Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)

Sunshine Biopharma's proprietary drug development program includes Adva-27a, the Company's flagship anticancer compound. A Topoisomerase II inhibitor, Adva-27a is a small molecule that has recently been shown to be effective at destroying Pancreatic Cancer cells, Multi-drug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935.

www.sunshinebiopharma.com

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:

Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.